Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Shell Companies

Financial Services
$10.90 +0.00%

+$0.00 today

Market cap
$264.62M
Beta
0.00
P/E (TTM)
36.7
EPS (TTM)
$0.29
52W Low $10.17High $10.63

Volume 0.00M

Average 0.11M

DMAA Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow dips below year-ago levels

Q1 FY2026 free cash flow of $91.25K (cash outflow) fell 63.7% year over year, behind the +22.8% change in trailing-twelve-month free cash flow. Sequentially, it fell 27.1% from the prior quarter.

What to watch

Whether quarterly growth recovers from -63.7% toward the trailing-twelve-month pace of +22.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$91.25K-27.1% QoQ
Last fiscal yearDec 2025
-$539.19K+182675.3% YoY
LTMMar 2026
-$379.19K+22.8% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.7%——
1 year+182675.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(539.19K) USD
Year-over-year change
-182675.3%

Free Cash Flow vs competitors

How DMAA compares with its peers on the latest reported figures

  • DMAA's LTM Mar 2026 free cash flow of $379.19K is the smallest of the 10 companies compared; the peer median is $891.94K.
  • Its year-over-year change of +22.8% is the 3rd highest of 4, against a peer median of +482.2%.
DMAA Competitors Peer median
Free Cash Flow for DMAA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LOKVLive Oak Acquisition Corp. V Class A Ordinary SharesFY2025$1.28M ———
TACOUBerto Acquisition Corp. UnitFY2025$1.26M ———
TACOBerto Acquisition Corp.FY2025$1.26M ———
MLACMountain Lake Acquisition Corp.FY2025$930.71K +482.2%-12.5%—
TACHTitan Acquisition Corp.LTM Mar 2026$891.94K +3328.3%——
RTACRenatus Tactical Acquisition Corp I Class A Ordinary SharesLTM Mar 2026$863.59K ———
SIMASIM Acquisition Corp. ILTM Mar 2026$745.56K -32.6%——
OYSEOyster Enterprises II Acquisition CorpFY2025$567.93K ———
ALFCenturion Acquisition Corp.LTM Mar 2026$463.43K ———
DMAADrugs Made In America Acquisition Corp. Ordinary SharesLTM Mar 2026$379.19K +22.8%——
Peer median (excluding DMAA) $891.94K+482.2%-12.5%—

Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.